Wang M, Herbst RS, Boshoff C (2021) Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med 27(8):1345–1356
Article CAS PubMed Google Scholar
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS et al (2022) Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20(5):497–530
Bade BC, Dela Cruz CS (2020) Lung cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med 41(1):1–24
Boumahdi S, de Sauvage FJ (2020) The great escape: tumour cell plasticity in resistance to targeted therapy. Nat Rev Drug Discov 19(1):39–56
Article CAS PubMed Google Scholar
Shen J, Li L, Yang T, Cohen PS, Sun G (2020) Biphasic mathematical model of cell-drug interaction that separates target-specific and off-target inhibition and suggests potent targeted drug combinations for multi-driver colorectal cancer cells. Cancers (Basel) 12(2):436
Article CAS PubMed Google Scholar
Alkebsi L, Wang X, Ohkawara H, Fukatsu M, Mori H, Ikezoe T (2021) Dasatinib induces endothelial-to-mesenchymal transition in human vascular-endothelial cells: counteracted by cotreatment with bosutinib. Int J Hematol 113(3):441–455
Article CAS PubMed Google Scholar
Liu C, Zhu X, Jia Y, Chi F, Qin K, Pei J, Zhang C et al (2021) Dasatinib inhibits proliferation of liver cancer cells, but activation of Akt/mTOR compromises dasatinib as a cancer drug. Acta Biochim Biophys Sin (Shanghai) 53(7):823–836
Article CAS PubMed Google Scholar
Huang WC, Kuo KT, Wang CH, Yeh CT, Wang Y (2019) Cisplatin resistant lung cancer cells promoted M2 polarization of tumor-associated macrophages via the Src/CD155/MIF functional pathway. J Exp Clin Cancer Res 38(1):180
Article PubMed PubMed Central Google Scholar
Hsu PC, Yang CT, Jablons DM, You L (2020) The crosstalk between src and Hippo/YAP signaling pathways in non-small cell lung cancer (NSCLC). Cancers (Basel) 12(6):1361
Article CAS PubMed PubMed Central Google Scholar
Fan PD, Narzisi G, Jayaprakash AD, Venturini E, Robine N, Smibert P, Germer S et al (2018) YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proc Natl Acad Sci U S A 115(26):E6030–E6038
Article CAS PubMed PubMed Central Google Scholar
Fuentes-Baile M, Ventero MP, Encinar JA, García-Morales P, Poveda-Deltell M, Pérez-Valenciano E, Barberá VM et al (2020) Differential effects of IGF-1R small molecule tyrosine kinase inhibitors BMS-754807 and OSI-906 on human cancer cell lines. Cancers (Basel) 12(12):3717
Article CAS PubMed Google Scholar
Xue L, Chen F, Yue F, Camacho L, Kothapalli S, Wei G, Huang S et al (2021) Metformin and an insulin/IGF-1 receptor inhibitor are synergistic in blocking growth of triple-negative breast cancer. Breast Cancer Res Treat 185(1):73–84
Article CAS PubMed Google Scholar
Zeng B, Liao X, Liu L, Zhang C, Ruan H, Yang B (2021) Thyroid hormone mediates cardioprotection against postinfarction remodeling and dysfunction through the IGF-1/PI3K/AKT signaling pathway. Life Sci 267:118977
Article CAS PubMed Google Scholar
Franks SE, Jones RA, Briah R, Murray P, Moorehead RA (2016) BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549. BMC Res Notes 9:134
Article PubMed PubMed Central Google Scholar
Dong AQ, Kong MJ, Ma ZY, Qian JF, Xu XH (2007) Down-regulation of IGF-IR using small, interfering, hairpin RNA (siRNA) inhibits growth of human lung cancer cell line A549 in vitro and in nude mice. Cell Biol Int 31(5):500–507
Article CAS PubMed Google Scholar
Reinmuth N, Kloos S, Warth A, Risch A, Muley T, Hoffmann H, Thomas M et al (2014) Insulin-like growth factor 1 pathway mutations and protein expression in resected non-small cell lung cancer. Hum Pathol 45(6):1162–1168
Article CAS PubMed Google Scholar
Siddle K (2011) Signalling by insulin and IGF receptors: supporting acts and new players. J Mol Endocrinol 47(1):R1–10
Article CAS PubMed Google Scholar
Lehman CE, Spencer A, Hall S, Shaw JJP, Wulfkuhle J, Petricoin EF, Bekiranov S et al (2021) IGF1R and src inhibition induce synergistic cytotoxicity in HNSCC through inhibition of FAK. Sci Rep 11(1):10826
Article CAS PubMed PubMed Central Google Scholar
Shen J, Li L, Yang T, Cheng N, Sun G (2019) Drug sensitivity screening and targeted pathway analysis reveal a multi-driver proliferative mechanism and suggest a strategy of combination targeted therapy for colorectal cancer cells. Molecules 24(3):623
Article PubMed PubMed Central Google Scholar
Awasthi N, Zhang C, Ruan W, Schwarz MA, Schwarz RE (2012) BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer. Mol Cancer Ther 11(12):2644–2653
Article CAS PubMed Google Scholar
Camidge DR, Otterson GA, Clark JW, Ignatius Ou SH, Weiss J, Ades S, Shapiro GI et al (2021) Crizotinib in patients with MET-amplified NSCLC. J Thorac Oncol 16(6):1017–1029
Article CAS PubMed Google Scholar
Chen Z, Chen Q, Cheng Z, Gu J, Feng W, Lei T, Huang J et al (2020) Long non-coding RNA CASC9 promotes gefitinib resistance in NSCLC by epigenetic repression of DUSP1. Cell Death Dis 11(10):858
Article CAS PubMed PubMed Central Google Scholar
Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z, Li W et al (2020) PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis 11(9):797
Article PubMed PubMed Central Google Scholar
Nepstad I, Hatfield KJ, Grønningsæter IS, Reikvam H (2020) The PI3K-Akt-mTOR signaling pathway in human acute myeloid leukemia (AML) cells. Int J Mol Sci 21(8):2907
Article CAS PubMed PubMed Central Google Scholar
Tan AC (2020) Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC). Thorac Cancer 11(3):511–518
Article PubMed PubMed Central Google Scholar
Bostner J, Karlsson E, Pandiyan MJ, Westman H, Skoog L, Fornander T, Nordenskjöld B et al (2013) Activation of akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit. Breast Cancer Res Treat 137(2):397–406
Article CAS PubMed Google Scholar
Lee S, Rauch J, Kolch W (2020) Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity. Int J Mol Sci 21(3):1102
Article CAS PubMed PubMed Central Google Scholar
Drosten M, Barbacid M (2020) Targeting the MAPK pathway in KRAS-driven tumors. Cancer Cell 37(4):543–550
Article CAS PubMed Google Scholar
Martínez-Alonso D, Malumbres M (2020) Mammalian cell cycle cyclins. Semin Cell Dev Biol 107:28–35
Hume S, Dianov GL, Ramadan K (2020) A unified model for the G1/S cell cycle transition. Nucleic Acids Res 48(22):12483–12501
Article CAS PubMed PubMed Central Google Scholar
Levy JMM, Towers CG, Thorburn A (2017) Targeting autophagy in cancer. Nat Rev Cancer 17(9):528–542
Article CAS PubMed Google Scholar
Li X, Yang KB, Chen W, Mai J, Wu XQ, Sun T, Wu RY et al (2021) CUL3 (cullin 3)-mediated ubiquitination and degradation of BECN1 (beclin 1) inhibit autophagy and promote tumor progression. Autophagy 17(12):4323–4340
Article CAS PubMed PubMed Central Google Scholar
Jia R, Bonifacino JS (2021) The ubiquitin isopeptidase USP10 deubiquitinates LC3B to increase LC3B levels and autophagic activity. J Biol Chem 296:100405
Article CAS PubMed PubMed Central Google Scholar
Wen W, Li X, Yin M, Wang H, Qin L, Li H, Liu W et al (2021) Selective autophagy receptor SQSTM1/ p62 inhibits Seneca Valley virus replication by targeting viral VP1 and VP3. Autophagy 17(11):3763–3775
Article CAS PubMed PubMed Central Google Scholar
Harrison PT, Vyse S, Huang PH (2020) Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol 61:167–179
留言 (0)